|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KIAA1551 |
Gene summary for KIAA1551 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KIAA1551 | Gene ID | 55196 |
| Gene name | retroelement silencing factor 1 | |
| Gene Alias | C12orf35 | |
| Cytomap | 12p11.21 | |
| Gene Type | protein-coding | GO ID | GO:0006325 | UniProtAcc | Q9HCM1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55196 | KIAA1551 | P83T-E | Human | Esophagus | ESCC | 1.13e-11 | 5.38e-01 | 0.1738 |
| 55196 | KIAA1551 | P84T-E | Human | Esophagus | ESCC | 3.37e-08 | 7.43e-01 | 0.0933 |
| 55196 | KIAA1551 | P89T-E | Human | Esophagus | ESCC | 3.93e-02 | 4.84e-01 | 0.1752 |
| 55196 | KIAA1551 | P107T-E | Human | Esophagus | ESCC | 3.41e-31 | 1.40e+00 | 0.171 |
| 55196 | KIAA1551 | P126T-E | Human | Esophagus | ESCC | 1.75e-02 | 4.18e-01 | 0.1125 |
| 55196 | KIAA1551 | P127T-E | Human | Esophagus | ESCC | 4.11e-19 | 4.62e-01 | 0.0826 |
| 55196 | KIAA1551 | P128T-E | Human | Esophagus | ESCC | 6.97e-12 | 7.96e-01 | 0.1241 |
| 55196 | KIAA1551 | P130T-E | Human | Esophagus | ESCC | 1.95e-24 | 5.89e-01 | 0.1676 |
| 55196 | KIAA1551 | NAFLD1 | Human | Liver | NAFLD | 2.25e-06 | 5.07e-01 | -0.04 |
| 55196 | KIAA1551 | S43 | Human | Liver | Cirrhotic | 1.08e-07 | -1.91e-01 | -0.0187 |
| 55196 | KIAA1551 | HCC1_Meng | Human | Liver | HCC | 5.19e-33 | -2.28e-02 | 0.0246 |
| 55196 | KIAA1551 | HCC2_Meng | Human | Liver | HCC | 1.57e-31 | 2.12e-01 | 0.0107 |
| 55196 | KIAA1551 | HCC1 | Human | Liver | HCC | 3.59e-08 | 4.75e+00 | 0.5336 |
| 55196 | KIAA1551 | HCC2 | Human | Liver | HCC | 2.36e-31 | 5.27e+00 | 0.5341 |
| 55196 | KIAA1551 | HCC5 | Human | Liver | HCC | 3.93e-18 | 3.46e+00 | 0.4932 |
| 55196 | KIAA1551 | S014 | Human | Liver | HCC | 4.12e-03 | 2.83e-01 | 0.2254 |
| 55196 | KIAA1551 | S028 | Human | Liver | HCC | 1.18e-07 | 3.32e-01 | 0.2503 |
| 55196 | KIAA1551 | S029 | Human | Liver | HCC | 8.39e-03 | 2.83e-01 | 0.2581 |
| 55196 | KIAA1551 | C04 | Human | Oral cavity | OSCC | 1.13e-02 | 3.67e-01 | 0.2633 |
| 55196 | KIAA1551 | C21 | Human | Oral cavity | OSCC | 3.49e-10 | 3.82e-01 | 0.2678 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KIAA1551 | SNV | Missense_Mutation | novel | c.2311N>T | p.Val771Phe | p.V771F | Q9HCM1 | protein_coding | deleterious(0) | possibly_damaging(0.839) | TCGA-A2-A0EX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| KIAA1551 | SNV | Missense_Mutation | c.3118N>A | p.Glu1040Lys | p.E1040K | Q9HCM1 | protein_coding | tolerated(0.12) | possibly_damaging(0.791) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| KIAA1551 | SNV | Missense_Mutation | novel | c.5055N>T | p.Lys1685Asn | p.K1685N | Q9HCM1 | protein_coding | deleterious(0.02) | possibly_damaging(0.814) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KIAA1551 | SNV | Missense_Mutation | c.4246G>A | p.Glu1416Lys | p.E1416K | Q9HCM1 | protein_coding | deleterious(0) | possibly_damaging(0.754) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| KIAA1551 | SNV | Missense_Mutation | c.191T>C | p.Leu64Pro | p.L64P | Q9HCM1 | protein_coding | tolerated(0.18) | benign(0.025) | TCGA-E2-A1BD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| KIAA1551 | SNV | Missense_Mutation | novel | c.4394A>G | p.Lys1465Arg | p.K1465R | Q9HCM1 | protein_coding | tolerated(0.08) | benign(0.13) | TCGA-E9-A1R6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| KIAA1551 | SNV | Missense_Mutation | c.3439T>C | p.Cys1147Arg | p.C1147R | Q9HCM1 | protein_coding | tolerated(0.05) | possibly_damaging(0.592) | TCGA-E9-A1RG-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| KIAA1551 | SNV | Missense_Mutation | novel | c.5216N>T | p.Arg1739Ile | p.R1739I | Q9HCM1 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-EW-A6S9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| KIAA1551 | SNV | Missense_Mutation | c.3286N>A | p.Asp1096Asn | p.D1096N | Q9HCM1 | protein_coding | deleterious(0.05) | benign(0.234) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| KIAA1551 | insertion | Frame_Shift_Ins | novel | c.3704_3705insTC | p.Asn1236GlnfsTer40 | p.N1236Qfs*40 | Q9HCM1 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |